Synteract CEO Steve Powell said the combined contract research organization (CRO) will offer biopharma a “one-stop shop solution for bringing their pediatric clinical trials to life.”
“Through the KinderPharm integration, our clients will be able to benefit from a single source model,” Powell told us.
The single source model will offer pharmacometric modeling and clinical trial simulation technologies, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis.
Powell added, “KinderPharm also brings a focus on the development of novel and rare pediatric drugs through pediatric formulation and juvenile toxicology expertise, as well as extensive US and European pediatric regulatory experience.”
Martin Graham, PhD, KinderPharm CEO and founder, will join the team as senior vice president of pediatric development, leading Synteract’s Center of Pediatric Development.
Graham will be joined by KinderPharm’s Lynne Georgopoulos, vice president pediatric development, Americas, and Synteract’s Dr. Martine Dehlinger-Kremer, vice president pediatric development, Europe, to build a leadership team.
Synteract earlier this year announced pediatrics as one of its “therapeutic centers of development.” Other centers include oncology, neuro-degenerative disorders, rare and orphan diseases, as well as dermatology – following the acquisition of Cu-Tech in July.
KinderPharm was previously involved in a strategic alliance with Worldwide Clinical Trials (WCT). Announced in April of this year, the alliance established a center of excellence for pediatric drug development and research. The relationship had since been dissolved.
